mRNA–LNP vaccine reduces H5N1 viral replication and mammary damage in dairy cows

A nucleoside-modified mRNA vaccine developed by researchers from the University of Pennsylvania and the US Department of Agriculture (USDA) significantly reduced viral replication and disease severity in lactating dairy cows experimentally...
Your Weekly Life Sciences Digest

Your Weekly Life Sciences Digest

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Researchers develop an optical wearable ring for continuous stress monitoring

Researchers at the University of Southern California (USC) and the University of Maryland have developed an AI-powered wearable ring that uses optical sensing instead of conventional skin electrodes to monitor physiological responses associated with stress. The technology, described in a study published in Science Advances on 13 November 2026, introduces a sensing approach called optical sensing of dermal activity (ODA), designed to track sweat gland activation and support longer-term...

Johnson & Johnson to acquire Ollin Biosciences for up to $3.3 billion

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with additional regulatory and commercial milestone payments of up to approximately $1.125 billion. The transaction will add OLN324, an investigational bispecific antibody in Phase III development for retinal vascular diseases, to J&J’s pharmaceutical pipeline. Completion is expected before the end of 2026, subject to regulatory approvals and customary closing conditions. The proposed...

The global peptide capacity race: who is investing in GLP-1 manufacturing?

The rapid growth of the GLP-1 drug market is driving a major expansion of global peptide manufacturing capacity. Pharmaceutical companies are investing in their own production networks, while contract development and manufacturing organisations (CDMOs) are building new facilities, acquiring specialist manufacturers and upgrading existing sites. Not all announced projects are dedicated exclusively to GLP-1 medicines. Several investments concern broader peptide manufacturing platforms that may also support GLP-1-related programmes, depending on...

Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion

Eli Lilly and Company has entered into a definitive agreement to acquire privately held biotechnology company Calytrix Bio, Inc. in a transaction valued at up to $1.5 billion in cash. The deal adds a preclinical antibody programme targeting mutant calreticulin (mCALR) to Lilly's pipeline for myeloproliferative neoplasms (MPNs), including essential thrombocythemia and myelofibrosis. Under the agreement, Calytrix shareholders may receive an upfront payment followed by additional payments linked to the...

WHO prequalification, inspections and the “WHO certificate”: understanding the differences

The World Health Organization (WHO) conducts inspections through its Inspection Services, primarily in connection with the assessment and ongoing oversight of products submitted to its Prequalification Programme. A separate mechanism, the WHO Certification Scheme, does not mean that WHO itself issues GMP certificates: the relevant documents are issued by competent national authorities using WHO-recommended formats. Scope of WHO prequalification and GMP inspections This article focuses primarily on human medicines and active...

GMP & Guidance

Documents available for download

EU–US GMP mutual recognition becomes fully operational for veterinary medicines

The European Union and the United States have completed the assessment of all EU Member States' competent authorities under the pharmaceutical Good Manufacturing Practice (GMP) Mutual Recognition Agreement (MRA)...

UAE EDE introduces new regulatory controls for peptide products and molecules

Read the official EDE Circular No. 46/2026 and download the full regulatory document in the TOP-Pharma Resource Centre. The Emirates Drug Establishment (EDE) has introduced a comprehensive regulatory framework for...

FDA updates its human drug facility inspection framework under ConOps 2.0

The US Food and Drug Administration (FDA) has updated its operating framework for evaluating and inspecting human drug manufacturing facilities. The revised Concept of Operations (ConOps), dated 21 October...

FDA proposes framework for individualized gene therapies as CMS expands access

The US Food and Drug Administration (FDA) has proposed a regulatory framework for individualized human genome editing therapies, while the Centers for Medicare & Medicaid Services (CMS) plans to...
spot_img

Professional Interpreters for
GMP Inspections

Clear Communication for Your GMP Inspection.
We provide expert on-site interpreters who understand pharmaceutical terminology to ensure smooth communication with the inspectors.